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Vascular tumor emboliAbstract Background: Loss of E-cadherin is a critical step for development and progression of
malignant tumors. CD10; a marker of non-neoplastic and neoplastic endometrial stroma, is asso-
ciated with aggressiveness of many epithelial malignancies.
Aims: To evaluate expression and correlation of E-cadherin and CD10 in endometrial lesions and
their possible role in differentiating atypical endometrial hyperplasia from endometrial carcinoma.
The association of E-cadherin and CD10 expression with clinico-pathological parameters of endo-
metrial carcinoma was also investigated.
Materials and methods: Fifty four cases including 28 endometrial carcinomas; 19 endometrial
hyperplasia and 7 cases of normal endometrial changes were enrolled for this study. The expression
of E-cadherin and CD10 was evaluated by immunohistochemistry using the streptavidin–biotin
technique.
Results: There was a strong association between malignant change of endometrial glands and mem-
brano-cytoplasmic localization of E-cadherin (p < 0.001). Expression of E-cadherin but not CD10
was signiﬁcantly higher in endometrial carcinomas compared to atypical endometrial hyperplasia
(p< 0.01). Expression of E-cadherin was not associated with CD10 expression in different endome-
trial lesions. High grade tumors expressed low levels of both E-cadherin (p< 0.01) and CD10
(p< 0.05) and serous endometrial carcinoma had low E-cadherin and CD10 expression compared
to endometrioid carcinoma (p< 0.01 and <0.05, respectively). Expression of both molecules
showed no association with depth of tumor invasion or FIGO stage. Tumors with lower E-cadherin
or CD10 expression had higher rates of vascular tumor emboli (p< 0.01 and <0.07, respectively).
Conclusions: Although expression of E-cadherin and CD10 in endometrial lesions was not corre-
lated, reduced expression of both molecules could be critical for progression of endometrial carci-
noma.
ª 2014 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
Open access under CC BY-NC-ND license.Introduction
Endometrial carcinoma is the sixth most common cancer of
women worldwide [1]. It is a primary malignant tumor arising
in the endometrium and has the potential to invade the
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vival rate is 96% if the cancer is diagnosed at a local stage, but
markedly decreases to 17% if diagnosed at an advanced stage
[3]. As invasion and metastasis at the time of diagnosis signif-
icantly worsen the prognosis, awareness of the biomarkers that
may be clinically relevant to malignant change of the endome-
trium is appreciated.
Cell–cell adhesion is essential to maintain the normal
morphological and functional properties of different epithe-
lial, endothelial and neural tissues. E-cadherin is a trans-
membrane epithelial cell adhesion protein with a
cytoplasmic domain connected to the actin cytoskeleton
through a-, b- and c-catenins. E-cadherin/catenin complexes
are important pre-requisites for normal intact epithelial lin-
ing [4,5]. Several in vitro studies correlated low expression
of E cadherin with progression of malignant tumors [6,7]
and disturbed expression of E-cadherin and b-catenin had
been implicated in the invasive and metastatic potential of
different epithelial tumors including breast [8,9], prostatic
[10], gastric [11] and thyroid carcinomas [12]. E-cadherin
down-regulation and re-localization were documented in oral
squamous cell carcinoma and its low expression was corre-
lated with poorly differentiated tumors, aggressive behavior
and low survival rate [13]. Additionally; disturbed E-cad-
herin/catenin adhesion complex had been described in sev-
eral gynecologic carcinomas, including cervical [14,15],
endometrial [16,17] and ovarian carcinomas [18]. In endome-
trial cancer, the role of E-cadherin molecule has not been
fully understood. It has been recently reported that methyl-
ation of several gene promoters including E-cadherin, ERa
and PR is involved in early progression of endometrial car-
cinoma. Never the less, the authors indicated a clear ten-
dency of increasing methylation of promoters of these
genes from benign to peri-tumoral to malignant endometrial
lesions [19].
CD10 is a 94 kDa zinc-dependent cell membrane metallo-
proteinase; also called the common acute lymphoblastic leu-
kemia antigen. It is involved in several biological activities
through regulation of signal transduction of bioactive neuro-
peptides and vasoactive peptides [20,21]. CD10 is considered
as a marker for germinal center cells of the normal lymphoid
tissue and their derivative follicular lymphomas [22]. It is
widely distributed in the kidney, liver, small intestine, pla-
centa, choroid plexus, brain, gonads, adrenal cortex and leu-
cocytes [23]. It was reported that CD10 expression in cancer
stromal cells is associated with neoplastic transformation,
tumor progression and biological tumor aggressiveness [24–
26]. In gynecologic pathology, CD10 is a sensitive marker
to identify normal and neoplastic endometrial stromal cells
[27]. It can be used perfectly to differentiate endometrial stro-
mal sarcoma from uterine cellular leiomyoma and leiomyo-
sarcoma [28].
Evaluation of the relationship between stromal expression
of CD10 and epithelial expression of E-cadherin in tumor pro-
gression is generally deﬁcient and the association between
these two molecules in endometrial carcinoma has not been
previously clariﬁed. The aims of this study are to evaluate
expression of E-cadherin and CD10 in atypical endometrial
hyperplasia and endometrial carcinoma by immunohistochem-
istry and to test the association between expression of each of
E-cadherin and CD10 with other clinical and pathological
parameters of endometrial carcinoma.Material and methods
Tissue samples
Formalin-ﬁxed parafﬁn-embedded endometrial tissue blocks
from 54 patients diagnosed within the Pathology Depart-
ment, Sohag University Hospital from January 2011 to
December 2012 were obtained for this study. These
included all cases diagnosed as endometrial carcinoma
(n= 28) or atypical endometrial hyperplasia (n= 14). Rep-
resentative cases of non atypical endometrial hyperplasia
(n= 5), proliferative endometrium (n= 4) and endome-
trium with secretory changes (n= 3) were also included
in this study. Approval to perform this work was obtained
from the Institutional Research Ethics Committee. The clin-
ical data of the investigated cases were obtained from
patients‘ clinical ﬁles.
Immunohistochemistry
The antibodies and chromogen detection system used in this
work were purchased from Thermo Scientiﬁc. Sections of
4 lm thick of the selected parafﬁn blocks were de-parafﬁ-
nized in xylene for 20 min, rehydrated in graded alcohol
and incubated in 0.5% hydrogen peroxide/methanol for
10 min to block endogenous peroxidase activity. The antigens
were retrieved by boiling for 10 min in 10 mM citrate buffer,
pH 6.0, using a microwave, followed by cooling to room tem-
perature for 20 min. After washing in phosphate buffered sal-
ine (PBS), different sections were incubated with ready to use
mouse monoclonal anti-E-cadherin (clone MS-1479R7,
Thermo Scientiﬁc) and mouse monoclonal anti-CD10 (clone
56C6, Thermo scientiﬁc) antibodies for overnight at 4 C.
Next day, the sections were washed in PBS before incubation
with goat anti-mouse biotinylated secondary antibody for
10 min at room temperature. The sections were then washed
in PBS, incubated with streptavidin for 10 min at room tem-
perature, washed and exposed to 3,30-diaminobenzidine tetra-
hydrochloride solution (DAB) to yield an insoluble brown
deposit. Finally, the sections were counterstained with hema-
toxylin, washed in running water, dehydrated in graded alco-
hol and mounted as usual. Sections of skin were used as a
positive control for E-cadherin expression and sections of
endometrial stromal tumor were used as a positive control
for CD10 expression. Replacement of the primary antibodies
with PBS worked as negative controls for the immunohisto-
chemistry process.
Scoring of immunoreactions and statistical analyses
The immunohistochemistry results were analyzed indepen-
dently of the clinico-pathological data. The expression level of
E-cadherin andCD10wasmeasured by the histoscore that com-
bines intensity of the immunoreactions with percentage of posi-
tive cells. Cells present in four 400· high power ﬁelds were
counted and scored in each case. The intensities of immunoreac-
tions were stated as negative, weakly positive, moderately
positive, or strongly positive. These four categories were
weighed as 0, 1, 3, and 10, respectively. The ﬁnal histoscore
was calculated by multiplying the intensity of immunoreaction
with percentage of positive cells [29]. Final score ranged
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scored cells were strongly positive.
The commercially available statistical software (IBM-SPSS
version 19.0 forWindows; IBMInc.,) was used for data analysis.
The frequency of a categorical observation among atypical
endometrial hyperplasia and endometrial carcinoma was
compared by Chi-Square Test (v2). Mann–Whitney U Test
and Kruskal–Wallis Test were used to compare the mean rank
of E-cadherin and CD10 histoscores among different study
groups. Bonferroni adjustment for pairwise analysis was
applied when more than two categories were compared. The
cut-off for signiﬁcance of all used statistical analyses was rated
as p< 0.05.
Results
Patients’ clinical and pathological characteristics
This study included 54 patients aged between 19 and 71 years
with a mean ± SD of 52.5 ± 11.2 years. Thirty three (61.1%)
of the patients were postmenopausal, while perimenopausal
and premenopausal status were recorded in 14 (25.9%) and
7 (13.0%) patients, respectively. All patients were presented
with abnormal uterine bleeding and clinical examination
revealed a palpable mass at uterine cervix in one patient.
The tissue specimens were radical hysterectomy and bilateral
salpingo-oophorectomy in 35 cases, dilatation and curettage
in 17 cases, vaginal hysterectomy in one case and endometrial
polypectomy in one case. Malignant endometrial lesions
present in 28 cases while endometrial hyperplastic lesions
present in 19 cases; of which 14 cases were atypical and 5 were
non-atypical hyperplasia.
Among the 28 cases of endometrial carcinomas, 17 had a
localized uterine mass and 11 had a diffusely thickened
endometrium and the tumor size ranged between 1 and
6 cm with a mean ± SD of 2.4 ± 1.4 cm. Histologically, 23
of the malignant lesions were endometrioid adenocarcinomas
versus 5 serous endometrial adenocarcinomas. Tumors were
graded as I, II and III in 9, 11 and 8 of the cases, respec-
tively. Two tumors were limited to the endometrium (FIGO
IA) and the tumor extended to inner half of myometrium
(FIGO IB) in 7 cases, to outer half of myometrium (FIGO
IC) in 7 cases, to uterine cervix (FIGO IIB) in 3 cases and
to serosal covering of the uterus (FIGO IIIA) in 6 cases.
Vascular tumor emboli were histologically evident in 10
out of the 25 radically excised malignant endometrial
lesions.
Proﬁle of E-cadherin and CD10 expression
Expression of E-cadherin and CD10 was demonstrated in all
cases of proliferative, secretory and hyperplastic endometrial
changes. Two cases of the 28 investigated endometrial carci-
nomas were E-cadherin negative and different two cases were
CD10-negative. E-cadherin was expressed by endometrial
glands while CD10 was expressed by endometrial stroma.
The encountered myometrium was always negative for both
E-cadherin and CD10 immunostaining. The expression of
E-cadherin was predominantly membranous in non neoplas-
tic endometrial tissue (Fig. 1A–C) while neoplastic lesions
showed predominantly mixed membranous and cytoplasmicimmunoreactions (Fig. 1D and E). There was a strong asso-
ciation between malignant change of endometrial glands and
membrano-cytoplasmic immunoreaction to anti-E-cadherin
antibody [v2 (1) = 11.5, p= 0.001]. Membrano-cytoplasmic
immune staining was demonstrated in 20 out of the 26 posi-
tive endometrial carcinomas compared to three of the 14
atypical endometrial hyperplasia. On the other hand, CD10
immunoreaction was membranous or membrano-cytoplasmic
with no recorded association with a speciﬁc pathological
endometrial change (Fig. 1F–I). In some occasions, it was dif-
ﬁcult to identify whether CD10 immunoreaction was mem-
branous or membrano-cytoplasmic especially in cases with
high histoscores. It was noted that CD10 expression made
a zone of stromal expression deep into tumors limited to
endometrium and to villoglandular endometrioid adenocarci-
nomas. Additionally, CD10 expression decreased remarkably
as the stroma became desmoplastic. The two cases with zero
histoscore of CD10 had a predominantly desmoplastic
stroma.
Expression of E cadherin and CD10 was detected in all cases
of atypical endometrial hyperplasia and expression of both was
retained in 92.6% of endometrial adenocarcinoma cases. The
histoscore of both E-cadherin and CD10 expression ranged
from 0 to 1000 and the median value of E-cadherin histoscore
was 378 and that of CD10 histoscore was 750.5. The 1st and
3rd quartiles of E-cadherin histoscore were 172 and 668.8,
respectively and those of CD10 histoscore were 468.8 and
921.3, respectively. Statistical analysis showed no association
between expression of E-cadherin and CD10 in hyperplastic
or neoplastic endometrial lesions.
The expression of E-cadherin was signiﬁcantly higher in
endometrial adenocarcinomas compared to atypical endome-
trial hyperplasia (Table 1). The mean rank of E-cadherin his-
toscore in adenocarcinomas was signiﬁcantly higher than the
corresponding mean rank of atypical endometrial hyperplasia
(Mann–Whitney U, p= 0.009). CD10 expression showed no
association with either of these two lesions (Mann–Whitney
U, p= 0.153).
The association of E-cadherin and CD10 expression with
different pathological parameters of endometrial adenocarci-
noma was tested (Table 1). Neither of these two molecules
showed signiﬁcant relationships to tumor gross type or tumor
size. The expression of both E-cadherin and CD10 molecules
was inversely associated with tumor grade. High grade
tumors tended to express signiﬁcantly low levels of both E-
cadherin (Kruskal–Wallis Test, p= 0.007) and CD10 (Krus-
kal–Wallis Test, p= 0.015). Using Bonferroni adjustment for
pairwise comparisons among different tumor grades, both
grade I and grade II tumors showed signiﬁcant higher expres-
sion of E-cadherin when compared to grade III tumors
(p= 0.045 and p= 0.005, respectively) while no signiﬁcant
difference of E-cadherin expression among grade I and grade
II tumors was observed. Similarly CD10 histoscores were sig-
niﬁcantly higher in grade I and grade III endometrial carcino-
mas compared to grade III lesions (p= 0.017 and p= 0.016,
respectively) and no recorded signiﬁcant difference of CD10
histoscores between grade I and grade II tumors was
observed. Compared to endometrioid adenocarcinoma;
serous endometrial adenocarcinoma had signiﬁcantly low his-
toscores of E-cadherin (Mann–Whitney U, p= 0.002) as well
as signiﬁcantly low histoscores of CD10 (Mann–Whitney U,
p= 0.048).
Figure 1 Membranous expression of E cadherin in proliferative (A), non-atypical (B) and atypical (C) endometrial hyperplasia
compared to membranous (D) and membrano-cytoplasmic (E) expression in endometrial adenocarcinoma. Stromal expression of CD10 in
proliferative (F), non-atypical (G) and atypical (H) endometrial hyperplasia and endometrial carcinoma (I). Original magniﬁcations are
200· in B and 400· in others.
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sive potential of endometrial adenocarcinoma was studied.
Although there was a steady decrease of E-cadherin histoscores
as the tumor becamemore invasive, this relationship was not sta-
tistically signiﬁcant (Kruskal–Wallis Test, p= 0.673). Similarly;
endometrial carcinomas with higher FIGO stage expressed lower
levels of E-cadherin; but the relationship did not reach the signif-
icance level (Kruskal–Wallis Test, p= 0.521). CD10 expression
showed no association with either depth of tumor invasion or
FIGO stage of uterine adenocarcinoma.More importantly, sta-
tistical analyses showed that tumors with lower histoscores of E-
cadherin had a signiﬁcantly higher potential to access vascular
spaces and form tumor emboli. The mean rank of E-cadherin
histoscores for tumor with positive vascular emboli was 7.85
compared to 16.43 for tumors in which vascular tumor emboli
were undetectable (Mann–Whitney U, p= 0.004). For CD10
molecule, decreased expression was also potentially associated
with a higher risk for the presence of vascular tumor emboli
(Mann–Whitney U, p= 0.067).
Discussion
Invasion andmetastasis are general hallmarks of tumor progres-
sion. Atypical endometrial hyperplasia and endometrial carci-
noma limited within the uterus can be cured surgically while
invasive tumors extended beyond uterus or accessed vascularchannels are no longer localized diseases and systemic postoper-
ative adjuvant therapy is usually required. The histopatholo-
gical differentiation between atypical endometrial hyperplasia
and well-differentiated endometrioid carcinoma is very tricky
particularly in a D&C biopsy [30]; and a differentiating marker
is still sought. Reduced cell–cell adhesiveness allows cancer cells
to disobey the normal social orders and allows invasive clones of
tumor cells to emerge. Additionally, the tumor stromal cells and
molecules of extracellular matrix play a vital role in tumor
spread [31,32]. In this study; E-cadherin; a well known epithelial
adhesion molecule and CD10; an endometrial stromal marker,
expression in cases of endometrial hyperplasia and endometrial
carcinoma were evaluated by immunohistochemistry.
Glandular expression of E-cadherin was demonstrated in all
benign and hyperplastic endometrial tissues and in the vast
majority of malignant endometrial lesions. The only two cases
with negative E-cadherin expression were serous adenocarcino-
mas. Previous reports showed a homogenous glandular expres-
sion of E-cadherin in the most normal, non-atypical and
atypical hyperplastic endometrial tissues and only heterogenous
expression in 18 out of 22 investigated endometrial adenocarci-
nomas [33]. In the series investigated by Shih and his colleagues,
both serous and clear cell endometrial adenocarcinomaswere E-
cadherin negative [17]. These results imply that reduced E-cad-
herin expression is important for the progression of endometrial
carcinoma.Malignant change of endometrial glands was associ-
Table 1 Correlation of E-cadherin and CD10 histoscores with different pathological parameters of endometrial carcinoma measured
by Mann–Whitney U Testa or Kruskal–Wallis Testb. Statistically signiﬁcant relationships are highlighted.
a Mann–Whitney U Test.
b Kruskal–Wallis Test, highlights refer to statistically signiﬁcant relationships.
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cytoplasmic expression of E-cadherin (p= 0.001); a ﬁnding that
could help in differentiation of atypical endometrial hyperplas-
tic lesions from early carcinomatous change. Such a re-distribu-
tion of E-cadherin molecule could be associated with
impairment of its intercellular adhesion function. Additionally,
reduced expression of this adhesion molecule was statistically
associatedwith a higher tumor grade (p< 0.01), with aggressive
histological subtype (serous versus endometrioid carcinoma,
p< 0.01) and with increased possibility or lymphovascular
invasion (p< 0.01); all of which are indicators of aggressive
tumor cell behavior. In the same context, E-cadherin histoscore
showed a steady decline as the tumor had a higher FIGO stage
(Table 1). This is concordant to previous reports about tumor
suppressor effects of E-cadherin in several epithelial tumors
[34] including endometrial carcinoma [33,35]. The only ﬁnding
that could argue against the potential protective effect of E-cad-
herin against progression of endometrial cancer is its higher
expression in endometrial carcinoma compared to atypical
endometrial hyperplasia (p< 0.01). This could be due to con-
sidering both membranous and cytoplasmic immunostaining
in the histoscore system. In addition, liberation of E-cadherin
molecule from cell membrane to the cytoplasm may be
associated with increased number of epitopes detected by the
monoclonal antibody; resulting in stronger immunoreaction
and hence higher histoscores.Expression of CD10 protein was detected as a membrano-
cytoplasmic molecule in the stromal cells of all non-malignant
endometrial tissues and in 26 of the 28 investigated endome-
trial carcinomas (Fig. 1F–I). The endometrial glands and the
myometrium were always CD10-negative. In a study which
included several normal and tumorous endometrial and myo-
metrial tissues; CD10 showed moderate to strong diffuse cyto-
plasmic immunoreaction within endometrial stromal cells with
no recorded positivity in endometrial glands, in myometrial
tissue or their derivative tumors. The ﬁnal conclusion was to
consider CD10 as a sensitive marker to identify endometrial
stromal cells and to differentiate endometrial stromal nodule
and low grade endometrial stromal sarcoma from cellular lei-
omyoma and low grade leiomyosarcoma [27]. There was no
signiﬁcant difference of CD10 expression among atypical
hyperplastic and neoplastic endometrial lesions (p= 0.153).
In superﬁcial endometrial tumors, CD10 tended to be strongly
expressed at the base of the tumor forming a zone between
tumor tissue and myometrium. CD10 expression decreased sig-
niﬁcantly in high grade tumors (p< 0.05) and low expression
of CD10 was associated with tumor invasion to vascular chan-
nels (p= 0.67). The two cases with negative CD10 expression
were high grade endometrioid adenocarcinoma and serous
carcinoma; both of which were of FIGO stage IIIA. All these
ﬁndings imply that CD10 is an endometrial stromal molecule
that could reduce progression of glandular endometrial
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mal expression of CD10 in normal endometrium and such
expression was down-regulated after carcinomatous change
and markedly reduced in high grade endometrial carcinoma
[36]. Additionally, it has been reported that CD10 expression
was demonstrated in ovarian surface epithelial tumors and
the immunoreaction decreased in advanced histological grades
[37]. The exact role of CD10 in cancer progression is a matter
of controversy. Although some reports considered CD10 as a
tumor suppressor molecule in certain tumors including ovarian
carcinoma [37] and renal cell carcinoma [38], CD10 seems to
have a tumor progression effect in others including large B cell
lymphoma [39] and urothelial and squamous cell carcinoma of
the urinary bladder [40,41]. Additionally, the expression of
stromal CD10 changed from negative in normal skin to mod-
erate and strong positive in dysplasia and squamous cell carci-
noma of the skin; respectively [42]. Stromal CD10 expression
was positively correlated with a large tumor size, high tumor
grade, presence of lymph node metastasis and low overall
survival of invasive duct carcinoma of the breast [43,44].
According to this study, there was no association between
expression of E-cadherin and CD10 in endometrial carcinoma
tissues. This ﬁnding cannot exclude potential augmenting func-
tions between the two molecules to reduce the progression of
endometrial carcinoma. Kim et al. demonstrated a signiﬁcant
association between CD10 expression and increased cytoplas-
mic rather than membranous expression of b-catenin in breast
cancer but showed no association between CD10 and E-cad-
herin expression [44]. It has been documented that CD10 is
structurally similar to matrix metalloproteinases and stromely-
sin [45]. Additionally, CD10 can lead to up-regulation of gene
expression of matrix metalloproteinase [46] which has
functional interactions between matrix metalloproteinases
and the E-cadherin/catenin complex [32]. Further studying
the expression and functional relationships between
E-cadherin, b-catenin and CD10 molecules in addition to
extracellular matrix metalloproteinases in endometrial carci-
noma is required to address this potential augmenting effect.
Conﬂict of interest
None declared.
Acknowledgments
Thanks to Marwa Mohammed and Walaa Abdelmohsen, the
laboratory specialists, Pathology Department, Faculty of
Medicine, Sohag University for their kind advice and support
for immunohistochemistry work.
References
[1] International World Cancer Research Fund. <http://
www.wcrf.org/cancer_statistics/cancer_facts/
endometrial_cancer_rates.php> [accessed date 2013].
[2] Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubik-
Huch RA, Tavassoli FA. Tumors of the uterine corpus. In:
Fattaneh AT, Devilee P, editors. World Health organization
classiﬁcation of tumors, pathology & genetics, tumors of the
breast and female genital organs. Lyon: IARC Press; 2003. p.
220–30.[3] Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J
Clin 2010;60:277–300.
[4] Hinck L, Nathke IS, Papkoff J, Nelson WJ. Dynamics of
cadherin/catenin complex formation: novel protein interactions
and pathways of complex assembly. J Cell Biol 1994;125:
1327–40.
[5] Piepenhagen PA, Nelson WJ. Deﬁning E-cadherin-associated
protein complexes in epithelial cells: plakoglobin, beta- and
gamma-catenin are distinct components. J Cell Sci 1993;104(Pt
3):751–62.
[6] Hashimoto M, Niwa O, Nitta Y, Takeichi M, Yokoro K.
Unstable expression of E-cadherin adhesion molecules in
metastatic ovarian tumor cells. Jpn J Cancer Res 1989;80:
459–63.
[7] Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A,
et al. E-cadherin-mediated cell-cell adhesion prevents
invasiveness of human carcinoma cells. J Cell Biol 1991;113:
173–85.
[8] Heimann R, Lan F, McBride R, Hellman S. Separating
favorable from unfavorable prognostic markers in breast
cancer: the role of E-cadherin. Cancer Res 2000;60:298–304.
[9] Mahler-Araujo B, Savage K, Parry S, Reis-Filho JS. Reduction
of E-cadherin expression is associated with non-lobular breast
carcinomas of basal-like and triple negative phenotype. J Clin
Pathol 2008;61:615–20.
[10] Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG.
Expression of E-cadherin in primary and metastatic prostate
cancer. Am J Pathol 1996;148:1375–80.
[11] Oka H, Shiozaki H, Kobayashi K, Tahara H, Tamura S, Miyata
M, et al. Immunohistochemical evaluation of E-cadherin
adhesion molecule expression in human gastric cancer.
Virchows Arch A Pathol Anat Histopathol 1992;421:149–56.
[12] Serini G, Trusolino L, Saggiorato E, Cremona O, De Rossi M,
Angeli A, et al. Changes in integrin and E-cadherin expression
in neoplastic versus normal thyroid tissue. J Natl Cancer Inst
1996;88:442–9.
[13] Pannone G, Santoro A, Feola A, Bufo P, Papagerakis P,
LoMuzio L, et al. The role of E-cadherin down-regulation in
oral cancer: CDH1 gene expression and epigenetic blockage.
Curr Cancer Drug Targets 2014;14:115–27.
[14] Carico E, Atlante M, Bucci B, Nofroni I, Vecchione A. E-
cadherin and alpha-catenin expression during tumor progression
of cervical carcinoma. Gynecol Oncol 2001;80:156–61.
[15] Carico E, Fulciniti F, Giovagnoli MR, Losito NS, Botti G,
Benincasa G, et al. Adhesion molecules and p16 expression in
endocervical adenocarcinoma. Virchows Arch 2009;455:245–51.
[16] Moreno-Bueno G, Hardisson D, Sarrio D, Sanchez C, Cassia R,
Prat J, et al. Abnormalities of E- and P-cadherin and catenin
(beta-, gamma-catenin, and p120ctn) expression in endometrial
cancer and endometrial atypical hyperplasia. J Pathol 2003;199:
471–8.
[17] Shih HC, Shiozawa T, Miyamoto T, Kashima H, Feng YZ,
Kurai M, et al. Immunohistochemical expression of E-cadherin
and beta-catenin in the normal and malignant human
endometrium: an inverse correlation between E-cadherin and
nuclear beta-catenin expression. Anticancer Res 2004;24:
3843–50.
[18] Veatch AL, Carson LF, Ramakrishnan S. Differential
expression of the cell-cell adhesion molecule E-cadherin in
ascites and solid human ovarian tumor cells. Int J Cancer 1994;
58:393–9.
[19] Di Domenico M, Santoro A, Ricciardi C, Iaccarino M,
Iaccarino S, Freda M, et al. Epigenetic ﬁngerprint in
endometrial carcinogenesis: the hypothesis of a uterine ﬁeld
cancerization. Cancer Biol Ther 2011;12:447–57.
[20] Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D,
et al. Neutral endopeptidase inhibits prostate cancer cell
E-cadherin and CD10 expression in atypical hyperplastic and malignant endometrial lesions 217migration by blocking focal adhesion kinase signaling. J Clin
Invest 2000;106:1399–407.
[21] Ishimaru F, Mari B, Shipp MA. The type 2 CD10/neutral
endopeptidase 24.11 promoter: functional characterization and
tissue-speciﬁc regulation by CBF/NF-Y isoforms. Blood
1997;89:4136–45.
[22] de Leval L, Ferry JA, Falini B, Shipp M, Harris NL. Expression
of bcl-6 and CD10 in primary mediastinal large B-cell
lymphoma: evidence for derivation from germinal center B
cells? Am J Surg Pathol 2001;25:1277–82.
[23] Maguer-Satta V, Besancon R, Bachelard-Cascales E. Concise
review: neutral endopeptidase (CD10): a multifaceted
environment actor in stem cells, physiological mechanisms,
and cancer. Stem Cells 2011;29:389–96.
[24] OgawaH, Iwaya K, IzumiM, KurodaM, SerizawaH, Koyanagi
Y, et al. Expression of CD10 by stromal cells during colorectal
tumor development. Hum Pathol 2002;33:806–11.
[25] Abdou AG. CD10 expression in tumour and stromal cells of
bladder carcinoma: an association with bilharziasis. APMIS
2007;115:1206–18.
[26] Bilalovic N, Sandstad B, Golouh R, Nesland JM, Selak I,
Torlakovic EE. CD10 protein expression in tumor and stromal
cells of malignant melanoma is associated with tumor
progression. Mod Pathol 2004;17:1251–8.
[27] McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive
and diagnostically useful immunohistochemical marker of
normal endometrial stroma and of endometrial stromal
neoplasms. Histopathology 2001;39:273–8.
[28] Chu PG, Arber DA, Weiss LM, Chang KL. Utility of CD10 in
distinguishing between endometrial stromal sarcoma and uterine
smooth muscle tumors: an immunohistochemical comparison of
34 cases. Mod Pathol 2001;14:465–71.
[29] Ahmed AR, Grifﬁths AB, Tilby MT, Westley BR, May FE.
TFF3 is a normal breast epithelial protein and is associated with
differentiated phenotype in early breast cancer but predisposes
to invasion and metastasis in advanced disease. Am J Pathol
2012;180:904–16.
[30] Zaino RJ, Kauderer J, Trimble CL, Silverberg SG, Curtin JP,
Lim PC, et al. Reproducibility of the diagnosis of atypical
endometrial hyperplasia: a Gynecologic Oncology Group study.
Cancer 2006;106:804–11.
[31] Hojilla CV, Mohammed FF, Khokha R. Matrix
metalloproteinases and their tissue inhibitors direct cell fate
during cancer development. Br J Cancer 2003;89:1817–21.
[32] Coussens LM, Werb Z. Matrix metalloproteinases and the
development of cancer. Chem Biol 1996;3:895–904.
[33] Carico E, Atlante M, Giarnieri E, Raffa S, Bucci B, Giovagnoli
MR, et al. E-cadherin and alpha-catenin expression in normal,
hyperplastic and neoplastic endometrium. Anticancer Res
2010;30:4993–7.[34] Wijnhoven BP, Dinjens WN, Pignatelli M. E-cadherin–catenin
cell–cell adhesion complex and human cancer. Br J Surg 2000;
87:992–1005.
[35] Zhang Y, Kangdong L, Minxia D, Chunyang L, Ziming D.
Expression of E-cadherin, b-catenin and uPA proteins in
endometrial carcinoma and its clinical signiﬁcance. Life Sci J
2013;10:5.
[36] Suzuki T, Kikkawa F, Ino K, Nagasaka T, Tamakoshi K,
Mizutani S. Imbalance between neutral endopeptidase 24.11 and
endothelin-1 expression in human endometrial carcinoma.
Oncology 2001;60:258–67.
[37] Khin EE, Kikkawa F, Ino K, Suzuki T, Shibata K, Kajiyama H,
et al. Neutral endopeptidase/CD10 expression in the stroma of
epithelial ovarian carcinoma. Int J Gynecol Pathol 2003;22:
175–80.
[38] Gohring B, Holzhausen HJ, Meye A, Heynemann H, Rebmann
U, Langner J, et al. Endopeptidase 24.11/CD10 is down-
regulated in renal cell cancer. Int J Mol Med 1998;2:409–14.
[39] Uherova P, Ross CW, Schnitzer B, Singleton TP, Finn WG. The
clinical signiﬁcance of CD10 antigen expression in diffuse large
B-cell lymphoma. Am J Clin Pathol 2001;115:582–8.
[40] Omran OM. CD10 and E-cad expression in urinary bladder
urothelial and squamous cell carcinoma. J Environ Pathol
Toxicol Oncol 2012;31:203–12.
[41] Murali R, Delprado W. CD10 immunohistochemical staining in
urothelial neoplasms. Am J Clin Pathol 2005;124:371–9.
[42] Jang TJ. Epithelial to mesenchymal transition in cutaneous
squamous cell carcinoma is correlated with COX-2 expression
but not with the presence of stromal macrophages or CD10-
expressing cells. Virchows Arch 2012;460:481–7.
[43] Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB,
Huntsman DG. Stromal CD10 expression in invasive breast
carcinoma correlates with poor prognosis, estrogen receptor
negativity, and high grade. Mod Pathol 2007;20:84–9.
[44] Kim HS, Kim GY, Kim YW, Park YK, Song JY, Lim SJ.
Stromal CD10 expression and relationship to the E-cadherin/
beta-catenin complex in breast carcinoma. Histopathology 2010;
56:708–19.
[45] Iwaya K, Ogawa H, Izumi M, Kuroda M, Mukai K.
Stromal expression of CD10 in invasive breast carcinoma:
a new predictor of clinical outcome. Virchows Arch 2002;440:
589–93.
[46] Rosano L, Varmi M, Salani D, Di Castro V, Spinella F, Natali
PG, et al. Endothelin-1 induces tumor proteinase activation and
invasiveness of ovarian carcinoma cells. Cancer Res 2001;61:
8340–6.
